Table 2

Baseline characteristics from trials in the indirect comparisons




Baricitinib 4 mg (N=159)MTX (N=284)Tocilizumab 8 mg/kg (N=286)MTX (N=287)Tocilizumab 8 mg/kg (N=292)MTX (N=257)Adalimumab 40 mg (N=274)MTX (N=186)Tofacitinib 5 mg (N=373)
Mean duration of RA, years1.
SJC, 66 joints16.416.
TJC, 68 joints272631.131.827.428.732.331.825.425.7
CRP, mg/L22243130232540412623

Patient’s Global Assessment of Disease, 0–100 mm VAS

MTX dosing informationMTX initiated at 10 mg/week and, if tolerated, increased to 20 mg/week by Week 8; if clinically indicated, an initial dosage of 7.5 mg one time per week and maximum dosage of 12.5 mg once weeklyMTX initiated at 7.5 mg, increasing to 15 mg at Week 4 and to 20 mg at Week 8; dose reduction to 10 mg weekly was permittedMTX initiated at 7.5 mg/week and was increased to a maximum of 20 mg/week by Week 8MTX initiated at 7.5 mg/week for the first 4 weeks. If tolerated, dosage was increased to 15 mg/week during Weeks 4–8, and to 20 mg/week at Week 9. Dosage could be reduced to as low as 7.5 mg/weekMTX initiated at 10 mg/week, with increments of 5 mg/week every 4 weeks to 20 mg/week by Week 8
Mean MTX dosing achieved, mg/week17.715.5

N/A (81% achieved 20 mg/week)

  • CRP, C reactive protein; DAS28, Disease Activity Score for 28 joints; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.